Your browser doesn't support javascript.
loading
4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.
Xu, Guozhang; Abad, Marta C; Connolly, Peter J; Neeper, Michael P; Struble, Geoffrey T; Springer, Barry A; Emanuel, Stuart L; Pandey, Niranjan; Gruninger, Robert H; Adams, Mary; Moreno-Mazza, Sandra; Fuentes-Pesquera, Angel R; Middleton, Steven A.
Affiliation
  • Xu G; Johnson & Johnson Pharmaceutical Research and Development, Medicinal Chemistry, 8 Clarke Drive, Cranbury, NJ 08512, USA. gxu4@prdus.jnj.com
Bioorg Med Chem Lett ; 18(16): 4615-9, 2008 Aug 15.
Article in En | MEDLINE | ID: mdl-18653333
ABSTRACT
Members of a novel class of 4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones were identified as potent dual ErbB-2/EGFR kinase inhibitors using concept-guided design approach. These compounds inhibited the growth of ErbB-2 over-expressing human tumor cell lines (BT474, N87, and SK-BR-3) in vitro. Compound 15 emerged as a key lead and showed significant ability to inhibit growth factor-induced receptor phosphorylation in SK-BR-3 cells (IC(50)=54 nM) and cellular proliferation in vitro (IC(50)=14, 58, and 58 nM for BT474, N87, and SK-BR-3 respectively). The X-ray co-crystal structure of EGFR with a close analog (17) was determined and validated our design rationale.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Chemistry, Pharmaceutical / Receptor, ErbB-2 / Protein Kinase Inhibitors / ErbB Receptors / Hydrazones Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2008 Type: Article

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Chemistry, Pharmaceutical / Receptor, ErbB-2 / Protein Kinase Inhibitors / ErbB Receptors / Hydrazones Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2008 Type: Article